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The tumour antigen PReferentially expressed Antigen of MElanoma (PRAME) is expressed in a variety of malignancies, including
breast cancer. We have analysed PRAME gene expression in relation to clinical outcome for 295 primary breast cancer patients.
Kaplan–Meier survival curves show a correlation of PRAME expression levels with increased rates of distant metastases and
decreased overall patient survival. This correlation existed both for the entire patient group (n¼295) and for the subgroup of
patients (n¼185) who did not receive adjuvant chemotherapy. Multivariable analysis indicated that PRAME is an independent marker
of shortened metastasis-free interval in patients who did not receive adjuvant chemotherapy. PRAME expression was associated with
tumour grade and negative oestrogen receptor status. We conclude that PRAME expression is a prognostic marker for clinical
outcome of breast cancer, independent of traditional clinicopathological markers.
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The expression of preferentially expressed antigen of melanoma
(PRAME) has been detected in a variety of cancers including
breast cancer, but its expression is low or absent in normal tissues
(Ikeda et al, 1997). The protein PRAME was first detected as a
tumour antigen in cells isolated from a melanoma, and high
PRAME expression has been detected in 88–95% of primary
melanomas (Ikeda et al, 1997). PRAME can inhibit retinoic
acid (RA) signalling leading to resistance of melanoma cells to
proliferation arrest induced by RA (Epping et al, 2005). The
function of PRAME in breast cancer and other cancers in which it
is expressed is still elusive (Epping and Bernards, 2006).
Among the tumour types expressing PRAME are breast cancers,
lung cancers, sarcomas, Wilms’ tumours, renal carcinomas,
medulloblastomas, head-and-neck cancers, lymphomas, and sev-
eral types of leukaemias (Ikeda et al, 1997; Neumann et al, 1998; Li
et al, 2002; Steinbach et al, 2002b; Boon et al, 2003; Radich et al,
2006; Willenbrock et al, 2006). Although many reports have
focused on the detection of PRAME mRNA transcripts, there
are few studies that have linked gene expression data directly
to clinical information. The expression of PRAME is associated
with poor prognosis in neuroblastoma: high PRAME expression
is associated with more advanced tumour stage, higher ages of
patients at diagnosis, and poor clinical outcome (Oberthuer et al,
2004). PRAME expression has been linked to good prognosis in
paediatric AML (Steinbach et al, 2002a), but other studies did not
find a significant correlation (Paydas et al, 2005).
We previously identified a gene expression profile that is
associated with the risk of early distant metastases in young breast
cancer patients (van ‘t Veer et al, 2002). The tumours of 78 women
with sporadic lymph node-negative breast cancer were selected to
search for a prognostic signature in their gene expression profiles.
We found that 231 genes were significantly associated with disease
outcome, one of which was PRAME. Serial computational analyses
of the data were conducted to generate a ‘prognosis classifier’
comprising an optimised number of 70 marker genes. PRAME
was part of the set of 231 ‘significant prognosis reporter genes’,
but not of the optimal set of 70, which together constitute the
prognosis classifier (van ‘t Veer et al, 2002). This classifier allowed
the categorisation of patients in a ‘good-prognosis’ and a
‘poor-prognosis’ group, as defined by the occurrence of distant
metastases within 5 years after initial diagnosis (van ‘t Veer et al,
2002).
In a subsequent validation study, the tumours of a series of
295 consecutive women with breast cancer were used to validate
the 70-gene prognostic profile (van de Vijver et al, 2002). The
genome-wide gene expression profiles of these tumours demon-
strated the prognostic power of this profile in predicting the
outcome of disease. The poor-prognosis signature was the strongest
predictor of the likelihood of distant metastases in all patients, with
a more accurate prediction of disease outcome than clinicopatho-
logical criteria and the NIH and St Gallen criteria (van de Vijver
et al, 2002). The prognosis classifier could be used to select
effectively those high-risk patients who would benefit from adjuvant
therapy, while reducing the number of patients who receive
unnecessary treatment and may suffer from the side effects.
Thus, the prognostic profile potentially provides a powerful tool
to tailor adjuvant systemic treatment of breast cancer (Buyse et al,
2006). Moreover, the prognostic power of the 70-gene profile
indicates that the ability to metastasise to distant sites is an early
and inherent genetic property of breast cancer, which argues against
the widely accepted idea that metastatic potential is acquired
relatively late during multistep tumorigenesis (Bernards and
Weinberg, 2002).
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sBecause PRAME was not part of the 70-gene prognosis classifier,
we have analysed the gene expression data set of the 295 breast
cancer patients from our previous study (van de Vijver et al, 2002)
for the expression levels of PRAME and found a remarkable
association between PRAME expression and poor clinical outcome.
We discuss these findings in the context of the recent insights in
PRAME function.
MATERIALS AND METHODS
Selection of patients
Tumours from a series of 295 consecutive women with breast
cancer were selected from the fresh-frozen tissue bank of the
Netherlands Cancer Institute according to the following criteria as
described previously (van de Vijver et al, 2002). The tumour was
primary invasive breast carcinoma less than 5cm in diameter at
pathological examination (pT1 or pT2); the apical axillary lymph
nodes were tumour-negative, as determined by a biopsy of the
infraclavicular lymph nodes; the age at diagnosis was 52 years or
younger; the calendar year of diagnosis was between 1984 and
1995; and there was no previous history of cancer, except
nonmelanoma skin cancer. All patients had been treated by
modified radical mastectomy or breast-conserving surgery,
including dissection of the axillary lymph nodes, followed by
radiotherapy if indicated. Among the 295 patients, 151 had lymph
node-negative disease (results on pathological examination, pN0)
and 144 had lymph node-positive disease (pNþ). All patients were
assessed at least annually for a period of at least 5 years. Follow-up
information was extracted from the medical registry of the
Netherlands Cancer Institute. The median follow-up among all
295 patients was 6.7 years (range, 0.05–18.3). There were no
missing data. The study was approved by the medical ethics
committee of the Netherlands Cancer Institute.
Isolation of RNA and microarray expression profiling
The isolation of RNA, labelling of complementary RNA (cRNA),
hybridisation of labelled cRNA to 25000 gene arrays, and
assessment of expression ratios were all performed as previously
described (Hughes et al, 2001; van ‘t Veer et al, 2002). In brief,
tumour material was snap-frozen in liquid nitrogen within 1h after
surgery. Frozen sections were stained with haematoxylin and
eosin; only samples that had more than 50 per cent tumour cells
were selected. Thirty 30-mm sections were used for the isolation of
RNA. Total RNA was isolated with RNAzolB and dissolved in
RNase-free water. Then 25mg of total RNA was treated with DNase
with use of the Qiagen RNase-free DNase kit and RNeasy spin
columns, and the RNA was then dissolved in RNase-free water to a
final concentration of 0.2mg per microlitre. Complementary RNA
was generated by in vitro transcription with the use of T7 RNA
polymerase and 5mg of total RNA and labelled with Cy3 or Cy5
(Cy Dye; Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Five micrograms of Cy-labelled cRNA from one breast cancer
tumour was mixed with the same amount of reverse-colour
Cy-labelled product from a reference pool that consisted of an equal
amount of cRNA from each patient. Labelled cRNAs were fragmented
to an average size of approximately 50–100 nucleotides by heating
the samples to 601C in the presence of 10mM zinc chloride and
adding a hybridisation buffer containing 1 M sodium chloride, 0.5 per
cent sodium sarcosine, 50mM morpholino-ethane sulphonic acid
(pH 6.5), and formamide (final concentration, 30 per cent at 401C);
the final volume was 3ml. The microarrays included 24479 biologic
oligonucleotides as well as 1281 control probes. The hybridisations
were performed in duplicates and with colour reversal. After
hybridisation, the slides were washed and scanned with a confocal
laser scanner (Agilent Technologies, Palo Alto, CA, USA). Fluores-
cence intensities on scanned images were quantified, and the values
w e r ec o r r e c t e df o rt h eb a c k g r o u n dl e v e la n dn o r m a l i s e d .
Statistical methods
The PRAME expression data were linked to the clinical database on
the basis of the Rosetta Bioinformatics patient identification
number (rosid). The probe sequence for PRAME was checked
using BLAST and was found to code only for PRAME and did not
match any other sequence. PRAME expression was quantified as
the logarithm of the intensity ratio with respect to a standard pool
of breast cancers. A normal probability plot indicated the existence
of two subgroups of patients with either relatively high or low
PRAME expression. An expectation–maximisation (EM) algo-
rithm was used to estimate the mean values and standard
deviations (s.d.) of the log2 ratio subgroups, which were treated
as normal distributions, an assumption that was supported by
histograms (Figure 1). The distance of every sample from the mean
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Figure 1 Histograms of PRAME expression levels (log2 ratios) for patients without adjuvant treatment (left; n¼185) and for all the patients (right;
n¼295).
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sof both groups measured in s.d. of that group was calculated. The
samples were assigned to the group with the smallest distance
in s.d. of that group. This method assigned 98 samples (33%) to
the high-expression group and 197 samples (67%) to the low-
expression group. The cutoff value for PRAME expression levels
in log2 was  1.45, which equals  0.4365 in log10.
Time in years to distant metastasis as first event was
measured from the date of diagnosis of the primary tumour.
For metastasis, the occurrence of a metastasis before any other
failure (locoregional recurrence or contralateral breast cancer
or death) was counted as an event, whereas all other patients
were censored at the time of another type of failure or end of
follow-up. For overall survival, death from any cause was counted
as an event, whereas patients still alive at the end of follow-up
were censored at that time. The P-values shown for the
Kaplan–Meier (KM) curves were calculated using a log rank
test. Cox regression analysis was used to analyse the prognostic
value of PRAME in addition to that of known clinicopathological
prognosticators.
RESULTS
The expression levels of PRAME mRNA in the primary breast
cancer biopsies of 295 patients used in our previous study (van de
Vijver et al, 2002) were analysed and matched to the clinical follow-
up data. There were 110 patients who received adjuvant systemic
chemotherapy, the majority of whom had lymph node-positive
disease (van de Vijver et al, 2002). These patients were separated
from the whole group, leaving 185 patients who had not received
adjuvant chemotherapy. In both cohorts of patients, two subgroups
for PRAME expression existed, with relatively low and relatively
high PRAME levels. Histograms were made to confirm the existence
of two subgroups for PRAME expression in each cohort (Figure 1).
Ninety-eight breast cancer samples (33%) were assigned to the high-
expression group and 197 samples (67%) to the low-expression
group, using a cutoff value of  1.45 in log2, which equals  0.4365
in log10 (see Materials and methods).
To evaluate the clinical relevance of PRAME expression,
Kaplan–Meier plots for overall survival and metastasis-free
interval were made. For the group of patients who did not receive
adjuvant chemotherapy, there were significant associations between
PRAME expression levels and shortened overall survival (Po0.001),
and PRAME expression levels and shortened metastasis-free interval
(Po0.001) (Figure 2). These data indicate that PRAME expression is
a prognostic marker for breast cancer progression.
Subsequently, we evaluated whether there was a relation
between PRAME expression levels and clinical follow-up in the
whole group of 295 patients. There were negative associations
between PRAME expression levels and overall survival (P¼0.0034)
and metastasis-free interval (P¼0.0029), that is high PRAME
levels were associated with poor outcome (Figure 3). Thus, PRAME
mRNA expression levels were inversely correlated with survival
in all the patients, irrespective of treatment, and KM plots
and P-values showed a more significant separation between
high- and low-risk samples for the patient group without adjuvant
chemotherapy compared to all 295 patients.
To determine whether PRAME expression is predictive for
adjuvant chemotherapy response, the subgroup of 110 patients
who received chemotherapy was analysed for PRAME expres-
sion and clinical outcome. Remarkably, there was no significant
difference between the treated patients with high and low
PRAME expressions with regard to overall survival (P¼0.95)
and metastasis-free interval (P¼0.91) (Figure 4). These data
indicate that the patients with high PRAME expression have had
significant benefit from the adjuvant chemotherapy and that in
this patient cohort, PRAME expression was predictive for response
to adjuvant chemotherapy.
Expression of PRAME was compared with clinicopathological
characteristics in a multivariable analysis. Independent prognostic
factors for metastasis-free interval were PRAME expression
(P¼0.006), age, lymph node status, mastectomy and tumour grade,
and vascularisation for the 185 patients who did not receive
chemotherapy (Table 1). In all, for the 295 patients, age, lymph
node status, tumour size, grade and vascularisation, and chemo-
therapy were independent prognostic factors for metastasis-free
interval (Table 2). PRAME expression was not significant in this
group (P¼0.11), probably due to the strong effect of chemotherapy.
To search for a possible relation between PRAME expression and
clinicopathological tumour characteristics, associations between
PRAME expression and clinical variables (age, tumour diameter,
number of positive axillary nodes, histologic grade, oestrogen
receptor (ER) status, vascular invasion, lymphatic infiltration) were
analysed. Only for grade and ER status, evidence for an association
with PRAME was found. In the 295-breast cancer patient group, high
PRAME expression levels were associated with poorly differentiated
tumours and low PRAME expression with well-differentiated
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Figure 2 Kaplan–Meier plots for metastasis-free interval (A) and overall
survival (B) for patients who did not receive adjuvant chemotherapy
(n¼185) categorised by PRAME mRNA levels (high PRAME: solid line; low
PRAME: dashed line). P-values were calculated by using a log rank test.
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stumours (Kruskal–Wallis test: P¼0.0005). Furthermore, the
expression of PRAME was associated with negative ER status, as
ER-negative patients had mostly high PRAME expression, whereas
ER-positive patients had mostly low PRAME expression (Mann–
Whitney test: Po0.0001). Although significant, this negative
association of PRAME with ER was not consistent among all
patients, which may be explained by the two patient subgroups with
respect to PRAME mRNA expression (Figure 1). The lymph node
status of patients was not directly associated with PRAME expression
(P¼0.678 for the nontreated patients; P¼0.691 for all patients).
In conclusion, our analyses provide evidence for an association
of high PRAME expression levels with poor clinical outcome of
premenopausal breast cancer with increased rates of distant
metastases and lower rates of overall survival.
DISCUSSION
In the present study, we have evaluated the prognostic value of
PRAME mRNA expression in 295 primary breast cancer biopsies. The
full-genome gene expression data of these patients were previously
used to validate the ‘poor-prognosis profile’ of 70 genes (van de Vijver
et al, 2002; van ‘t Veer et al,2 0 0 2 ) .U s i n gt h i sl a r g ed a t as e t ,w eh a v e
demonstrated that PRAME is a prognostic marker for metastasis-free
interval and overall survival. These data are reminiscent of a report
showing that the expression of PRAME is associated with poor
prognosis in neuroblastoma (Oberthuer et al, 2004).
Recently, an association between PRAME expression and
unfavourable disease outcome was shown in a study involving
103 breast cancer biopsies in which PRAME mRNA was detected in
B53% of tumour specimens (Doolan et al, 2008). The presence of
PRAME expression was associated with shortened disease-free
survival and overall survival in all breast cancer cases (Doolan
et al, 2008). In the cases in which adjuvant chemotherapy was
administrated, an association existed between PRAME expression
and shortened relapse-free survival (Doolan et al, 2008). In our
study, we provide evidence that PRAME expression is a prognostic
marker for metastasis-free interval and overall survival in primary
breast cancer. We also demonstrate that the strongest correlation
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Figure 4 Kaplan–Meier plots for metastasis-free interval (A) and overall
survival (B) for patients who received adjuvant chemotherapy (n¼110)
categorised by PRAME mRNA levels (high PRAME: solid line; low PRAME:
dashed line). P-values were calculated by using a log rank test.
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Figure 3 Kaplan–Meier plots for metastasis-free interval (A) and overall
survival (B) for all patients (n¼295) categorised by PRAME mRNA levels
(high PRAME: solid line; low PRAME: dashed line). P-values were calculated
by using a log rank test.
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sexists for patients who did not receive adjuvant chemotherapy,
indicating that PRAME has prognostic power in primary breast
cancer. Therefore, the data of the previous study (Doolan et al,
2008) are fully consistent with the conclusion of the present larger
study based on 295 patients and a subgroup of 185 patients who did
not receive chemotherapy. Our data differ from those of Doolan
et al (2008), in that we find that PRAME expression predicts benefit
of chemotherapy (Figure 4). However, given this discrepancy,
additional tumour series should be evaluated to address the
significance of PRAME as a biomarker of chemotherapy response.
We have found recently that PRAME is a corepressor of the RA
receptor and harbours seven ‘nuclear receptor boxes’, motifs that
allow interaction with nuclear receptors (Epping et al, 2005). This
finding begs the question whether the function of PRAME in breast
cancer progression is also to inhibit the function of specific nuclear
receptors. In our study, PRAME expression was found to be higher
in the ER-negative breast tumours, suggesting that PRAME does
not act on ER. Consistent with this, we did not observe an effect of
PRAME expression on ER or progesterone receptor activity
(Epping et al, 2005). Similarly, we observed lower RARa levels in
tumours having high PRAME expression, suggesting that PRAME
may also not act through RARa in breast cancer. Which nuclear
receptor (if any) is targeted by PRAME in breast cancer remains
elusive at present.
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